Genetic determinants of aromatase inhibitor-related arthralgia: The B-ABLE cohort study

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 385-395

  Garcia Giralt, Natalia ^a,b   Rodríguez Sanz, María ^a,b   Prieto Alhambra, Daniel ^a,b,c,d   Servitja, Sonia ^e,f   Torres Del Pliego, Elisa ^a   Balcells, Susana ^g   Albanell, Joan ^e,f   Grinberg, Daniel ^g   Diez Perez, Adolfo ^a,b   Tusquets, Ignasi ^e,f   Nogués, Xavier ^a,b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e Medical Oncology Department   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aromatase inhibitors; Arthralgia; Breast cancer; SNP

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; COLECALCIFEROL; ESTROGEN; EXEMESTANE; LETROZOLE; VITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; CYP17A1 PROTEIN, HUMAN; STEROID 17ALPHA MONOOXYGENASE; VDR PROTEIN, HUMAN;

ADULT; ALLELE; ARTHRALGIA; ARTICLE; BREAST CANCER; COHORT ANALYSIS; CYP17A1 GENE; CYP27B1 GENE; DISEASE SEVERITY; DRUG WITHDRAWAL; EARLY CANCER; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; VDR GENE; VISUAL ANALOG SCALE; VITAMIN D DEFICIENCY; AGED; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED; PATHOLOGY;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; AGED; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, CALCITRIOL; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84881476987     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2638-3     Document Type: Article

References (30)

1. Kudachadkar R, O'Regan RM (2005) Aromatase Inhibitors as adjuvant therapy for postmenopausal patients with early stage breast Cancer. CA Cancer J Clin 55:145-163. doi: 10.3322/canjclin.55.3.145
2. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98:1802-1810. doi: 10.1002/cncr.11745
3. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942. doi: 10.1200/jco.2011.38.0261
4. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883. doi: 10.1200/jco.2007.10.7573
5. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682. doi: 10.1200/jco.2010.28.5064
6. Mao J, Su HI, Feng R, Donelson M, Aplenc R, Rebbeck T, Stanczyk F, DeMichele A (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8. doi: 10.1186/bcr2813
7. Flores CA, Shughrue P, Petersen SL, Mokha SS (2003) Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 118:769-778
8. Blomqvist A (2000) Sex hormones and pain: a new role for brain aromatase? J Comp Neurol 423:549-551. doi: 10.1002/1096-9861(20000807
9. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthr Rheum 52:2594-2598
10. 2 agonists repress transcription of proinflammatory genes. J Immunol 180:630-636
11. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26:3147-3152. doi: 10.1200/JCO.2007.15.4005
12. Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I (2010) Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas 66:291-297. doi: 10.1016/j.maturitas.2010.03. 012
13. Prieto-Alhambra D, Javaid M, Servitja S, Arden N, Martinez-GarcÃa M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2010) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125:869-878. doi: 10.1007/s10549-010-1075-9
14. Servitja S, Nogués X, Prieto-Alhambra D, Martínez- García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I (2011) Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. The Breast 21(1):95-101. doi: 10.1016/j.breast.2011.09.001
15. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629. doi: 10.1200/jco.2005.09.121
16. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung C-L, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen A-L, Zhai G, Macdonald HM, Forouhi NG, Loos RJF, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson J-O, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin M-R, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 376:180-188. doi: 10.1016/S0140- 6736(10)60588-0
17. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H (1996) Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11:306-311
18. Enjuanes A, Garcia-Giralt N, Supervía A, Nogués X, Ruiz-Gaspà S, Bustamante M, Mellibovsky L, Grinberg D, Balcells S, Díez-Pérez A (2006) A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone 38:738-743
19. Zarrabeitia MT, Hernandez JL, Valero C, Zarrabeitia AL, Garcia-Unzueta M, Amado JA, Gonzalez-Macias J, Riancho JA (2004) A common polymorphism in the 5′-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 150:699-704. doi: 10.1530/eje.0.1500699
20. Langdahl G, Brixen E (2000) Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures. Eur J Clin Invest 30:608-617
21. Todd KH, Funk JP (1996) The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 3:142-146. doi: 10.1111/j.1553-2712.1996.tb03402.x
22. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57:289-300. doi: 10.2307/2346101
23. Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, Stewart PM, Arlt W (2007) Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 21:1958-1968. doi: 10.1210/me.2007-0066
24. Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM (2009) Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs 32:143-150. doi: 10.1097/01.NCC. 0000339262.44560.92
25. Arai H, Miyamoto K-I, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y, Takeda E (2001) The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 16:1256-1264. doi: 10.1359/jbmr.2001.16.7.1256
26. Takeyama K-I, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S (1997) 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277:1827-1830. doi: 10.1126/science.277.5333.1827
27. Rastelli A, Taylor M, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis M (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129:107-116. doi: 10.1007/s10549-011- 1644-6
28. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(suppl 1):S3-S18. doi: 10.1016/j.ctrv.2008.03.007
29. Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407-1416. doi: 10.1093/annonc/mdn164
30. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2008) Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. Eur J Endocrinol 158:571-576. doi: 10.1530/EJE-07-0844